Pain management – Talk Bio

FDA Approves Vertex’s Journavx: First Non-Opioid Pain Medication in Decades

3 months ago talkbio0Tagged Acute onset pain, Approved, Journavx, Non-Opioid, Opioids, Pain management, Suzetrigine, United States Food and Drug Administration

Journavx, suzetrigine, non-opioid, acute pain, FDA approval, Vertex Pharmaceuticals, pain management, opioid alternative

Tris Pharma Achieves Significant Milestone with Non-Opioid Painkiller Cebranopadol in Phase III Trials

3 months ago talkbio0Tagged abuse potential, Agonist, Cebranopadol, Dual-NMR, non-opioid pain medication, Pain management, Phase 3 Clinical Trials, Reduced, Tris Pharma

Non-opioid pain medication, Cebranopadol, Tris Pharma, Phase III trials, Pain management, Reduced abuse potential, Dual-NMR agonist

FDA Approves Protega’s 10 mg Abuse-Deterrent Opioid Roxybond for Pain Management

6 months ago talkbio0Tagged abuse-deterrent, Approved, Opioids, Pain management, Protega Pharmaceuticals, Roxybond, SentryBond technology, United States Food and Drug Administration

FDA approval, Protega Pharmaceuticals, Roxybond, abuse-deterrent opioid, pain management, SentryBond technology

Vertex Unveils Promising Data on Non-Opioid Painkiller Suzetrigine Ahead of FDA Decision

6 months ago talkbio0Tagged Acute onset pain, Approved, Inhibitor, Non-opioid painkiller, Pain management, Suzetrigine, United States Food and Drug Administration

Suzetrigine, non-opioid painkiller, acute pain, FDA approval, Vertex Pharmaceuticals, NaV1.8 inhibitor, pain management

Grünenthal Acquires US-Based Valinor Pharma for $250 Million

9 months ago talkbio0Tagged Acquisition, Drug Industry, expansion, Grünenthal, Market, Movantik, naloxegol, Pain management, Pharma, U.S., Valinor

Grünenthal, Valinor Pharma, acquisition, Movantik, naloxegol, opioid-induced constipation, pain management, US market expansion, pharmaceutical industry